Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026 - Financial News Media

Palm Beach, FL - September 20, 2021 – FinancialNewsMedia.com News Commentary – Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements...

ONCY : 2.16 (-0.82%)
ONC.TO : 2.72 (-0.37%)
CRVS : 7.02 (-0.14%)
IPHA : 6.95 (-0.71%)
SURF : 7.73 (-3.13%)
CLVS : 4.68 (+1.52%)
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026

PALM BEACH,  Fla., /PRNewswire/ -- Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements have helped in the development of more effective,...

ONCY : 2.16 (-0.82%)
ONC.TO : 2.72 (-0.37%)
CRVS : 7.02 (-0.14%)
IPHA : 6.95 (-0.71%)
SURF : 7.73 (-3.13%)
CLVS : 4.68 (+1.52%)
Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program

--Initial data from LuMIERE study of targeted radiotherapy candidate FAP-2286 also expected in 2022

CLVS : 4.68 (+1.52%)
Non-Metastatic Castration Resistant Prostate Cancer Treatment Market- Overview by Manufactures,Business Analysis, Opportunity, Industry Growth, and Forecast to 2029

Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2029"which delivers detailed overview of the global non-metastatic castration resistant prostate cancer treatment...

CLVS : 4.68 (+1.52%)
NOVN : 8.23 (-2.72%)
AZN.LN : 8,939.000 (+3.13%)
Hearing Assistive Technology (HAT) Market: Top Countries Segmented by Applications and Geography Trends, Growth, Revenue, Market Impact and Precise Outlook 2029

Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2029" which delivers detailed overview of the hearing assistive technology (HAT) market in terms of market segmentation...

CLVS : 4.68 (+1.52%)
NOVN : 8.23 (-2.72%)
AZN.LN : 8,939.000 (+3.13%)
Clovis Oncology Announces Availability of and Reimbursement for Rubraca(R) (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca (rucaparib) is now available and reimbursed in Switzerland. The Swiss authority responsible for the authorization and supervision of therapeutic...

CLVS : 4.68 (+1.52%)
Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission ("SEC") to renew its previously established ATM facility under...

JPM : 162.76 (+0.98%)
CLVS : 4.68 (+1.52%)
Clovis (CLVS) Q2 Earnings Miss, PARP Drug Rubraca Sales Down

Clovis (CLVS) reports wider-than-expected loss for second-quarter 2021. Sales of the company's sole marketed drug, Rubraca, decreased year over year due to COVID-19 impacts.

BMY : 60.94 (+0.51%)
VRTX : 183.06 (-1.10%)
RGEN : 318.81 (-1.67%)
CLVS : 4.68 (+1.52%)
Clovis Oncology (CLVS) Reports Q2 Loss, Lags Revenue Estimates

Clovis (CLVS) delivered earnings and revenue surprises of -7.02% and -9.78%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CLVS : 4.68 (+1.52%)
Clovis: Q2 Earnings Snapshot

BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Wednesday reported a loss of $66.4 million in its second quarter.

CLVS : 4.68 (+1.52%)

Barchart Exclusives

Commodities: Game of Thrones
The drama in Commodities seems drawn straight from the book and television series, with almost as much carnage. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar